/connect-gujarat-english/media/post_banners/6f8d86fc15ad631cb3d1107042431d13e2987d40f1aee222c02be15dedcacc52.webp)
Follow Us
Lupin stated on Friday that the antiviral medicine Molnupiravir will be available in India under the brand name Molnulup for the treatment of COVID-19 adults.
"The drug has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult patients with COVID-19, with SpO2 > 93%, and the ones who have a high risk of progression of the disease including hospitalisation," the company said in a statement. Molnupiravir is an oral antiviral that has been licenced for the treatment of mild-to-moderate COVID-19 in adults by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).
Molnupiravir, when taken orally, prevents SARS-CoV-2, the virus that causes COVID-19, from replicating. Molnupiravir has been proven to be effective against the most frequent SARSCoV-2 variations, including the Gamma, Delta, and Mu forms, in both preclinical and clinical studies.
Also see COVID-19: Molnupiravir's Strange Case and Why the ICMR Is Against Its Use
Molnupiravir should be started as soon as feasible after a COVID-19 diagnosis and no later than five days after symptoms appear.
Clinical evidence suggests that Molnupiravir could be a game-changer for the most immunosuppressed and fragile patients. Obesity, advanced age (>60 years), diabetes, and heart disease are examples, according to the Mumbai-based firm.
Rajeev Sibal, President - India Region Formulations (IRF), Lupin, commented on the development, saying, "The approval for Molnulup is timely as India is again experiencing an upward spike in COVID-19 incidences. In the past two years since COVID-19 has emerged, there is a need for an oral antiviral medicine that can be prescribed by the Healthcare practitioners and then taken by the patients conveniently at home. Through our strong distribution network, we will make Molnulup readily available at pharmacies Pan India to meet patient demand."
Lupin develops and promotes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, South Africa, and Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.